Analyst Recommends ‘Buy’ for Disc Medicine Due to Promising Developments in Bitopertin’s Accelerated Approval Pathway
Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Disc Medicine (IRON – Research Report) and keeping the price target ...